Clinical trial
Preventive Treatment of VETD in Patients With Multiple Myeloma Receiving Chemotherapy With Thalidomide or Lenalinomide
NCT01268774 is registered in ClinicalTrials.gov with LEO Pharma as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Preventive Treatment of VETD in Patients With Multiple Myeloma Receiving Chemotherapy With Thalidomide or Lenalinomide
- Lead sponsor
- LEO Pharma
- Phase
- Observational
- Overall status
- Completed
- Start date
- February 28, 2009
- Completion date
- July 31, 2011
- Enrollment
- 529 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.